{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:16:14Z","timestamp":1782587774618,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glycogen storage disease type 1a (GSD Ia) is an inborn error of metabolism caused by a defect in glucose-6-phosphatase (G6PC1) activity, which induces severe hepatomegaly and increases the risk for liver cancer. Hepatic GSD Ia is characterized by constitutive activation of Carbohydrate Response Element Binding Protein (ChREBP), a glucose-sensitive transcription factor. Previously, we showed that ChREBP activation limits non-alcoholic fatty liver disease (NAFLD) in hepatic GSD Ia. As ChREBP has been proposed as a pro-oncogenic molecular switch that supports tumour progression, we hypothesized that ChREBP normalization protects against liver disease progression in hepatic GSD Ia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Hepatocyte-specific\n                      <jats:italic>G6pc<\/jats:italic>\n                      knockout (L-\n                      <jats:italic>G6pc<\/jats:italic>\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      ) mice were treated with AAV-shChREBP to normalize hepatic ChREBP activity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Hepatic ChREBP normalization in GSD Ia mice induced dysplastic liver growth, massively increased hepatocyte size, and was associated with increased hepatic inflammation. Furthermore, nuclear levels of the oncoprotein Yes Associated Protein (YAP) were increased and its transcriptional targets were induced in ChREBP-normalized GSD Ia mice. Hepatic ChREBP normalization furthermore induced DNA damage and mitotic activity in GSD Ia mice, while gene signatures of chromosomal instability, the cytosolic DNA-sensing cGAS-STING pathway, senescence, and hepatocyte dedifferentiation emerged.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, our findings indicate that ChREBP activity limits hepatomegaly while decelerating liver disease progression and protecting against chromosomal instability in hepatic GSD Ia. These results disqualify ChREBP as a therapeutic target for treatment of liver disease in GSD Ia. In addition, they underline the importance of establishing the context-specific roles of hepatic ChREBP to define its therapeutic potential to prevent or treat advanced liver disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40170-023-00305-3","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T10:06:54Z","timestamp":1682071614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia"],"prefix":"10.1186","volume":"11","author":[{"given":"Martijn G. S.","family":"Rutten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne H.","family":"Hoogerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent W.","family":"Bloks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trijnie","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore A.","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aycha","family":"Bleeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam H.","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justina C.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"van den Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Mithieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Rajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Mardinoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana C. J.","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"van de Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike H.","family":"Oosterveer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"305_CR1","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10545-014-9772-x","volume":"38","author":"JY Chou","year":"2015","unstructured":"Chou JY, Jun HS, Mansfield BC. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase\/glucose-6-phosphate transporter complexes. J Inherit Metab Dis. 2015;38:511\u20139. https:\/\/doi.org\/10.1007\/s10545-014-9772-x.","journal-title":"J Inherit Metab Dis"},{"key":"305_CR2","doi-asserted-by":"publisher","unstructured":"Rake J, Visser G, Labrune P, Leonard J, Ullrich K, Smit P. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002;161 Suppl:S20\u201334. https:\/\/doi.org\/10.1007\/S00431-002-0999-4.","DOI":"10.1007\/S00431-002-0999-4"},{"key":"305_CR3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cmet.2017.07.004","volume":"26","author":"A Abdul-Wahed","year":"2017","unstructured":"Abdul-Wahed A, Guilmeau S, Postic C. Sweet Sixteenth for ChREBP: Established Roles and Future Goals. Cell Metab. 2017;26:324\u201341. https:\/\/doi.org\/10.1016\/j.cmet.2017.07.004.","journal-title":"Cell Metab"},{"key":"305_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jhep.2012.09.030","volume":"58","author":"J Calderaro","year":"2013","unstructured":"Calderaro J, Labrune P, Morcrette G, Rebouissou S, Franco D, Pr\u00e9vot S, et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type i. J Hepatol. 2013;58:350\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2012.09.030.","journal-title":"J Hepatol"},{"key":"305_CR5","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1093\/hmg\/ddv230","volume":"24","author":"GY Kim","year":"2015","unstructured":"Kim GY, Lee YM, Cho JH, Pan CJ, Jun HS, Springer DA, et al. Mice expressing reduced levels of hepatic glucose-6-phosphatase-a activity do not develop age-related insulin resistance or obesity. Hum Mol Genet. 2015;24:5115\u201325. https:\/\/doi.org\/10.1093\/hmg\/ddv230.","journal-title":"Hum Mol Genet"},{"key":"305_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.bbadis.2016.11.029","volume":"1863","author":"K Iizuka","year":"2017","unstructured":"Iizuka K. The transcription factor carbohydrate-response element-binding protein (ChREBP): A possible link between metabolic disease and cancer. Biochim Biophys Acta - Mol Basis Dis. 2017;1863:474\u201385. https:\/\/doi.org\/10.1016\/j.bbadis.2016.11.029.","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"305_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.molmet.2014.05.005","volume":"3","author":"A Abdul-Wahed","year":"2014","unstructured":"Abdul-Wahed A, Gautier-Stein A, Casteras S, Soty M, Roussel D, Romestaing C, et al. A link between hepatic glucose production and peripheral energy metabolism via hepatokines. Mol Metab. 2014;3:531\u201343. https:\/\/doi.org\/10.1016\/j.molmet.2014.05.005.","journal-title":"Mol Metab"},{"key":"305_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31198","author":"Y Lei","year":"2020","unstructured":"Lei Y, Hoogerland JA, Bloks VW, Bos T, Bleeker A, Wolters H, et al. Hepatic ChREBP activation limits NAFLD development in a mouse model for Glycogen Storage Disease type Ia. Hepatology. 2020. https:\/\/doi.org\/10.1002\/hep.31198.","journal-title":"Hepatology"},{"key":"305_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"305_CR10","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1053\/j.gastro.2010.12.006","volume":"140","author":"DF Calvisi","year":"2011","unstructured":"Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011;140:1071-1083.e5. https:\/\/doi.org\/10.1053\/j.gastro.2010.12.006.","journal-title":"Gastroenterology"},{"key":"305_CR11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1080\/15384101.2018.1489182","volume":"17","author":"S Ribback","year":"2018","unstructured":"Ribback S, Che L, Pilo MG, Cigliano A, Latte G, Pes GM, et al. Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. Cell Cycle. 2018;17:1496\u2013512. https:\/\/doi.org\/10.1080\/15384101.2018.1489182.","journal-title":"Cell Cycle"},{"key":"305_CR12","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/hep.25600","volume":"55","author":"M Evert","year":"2012","unstructured":"Evert M, Calvisi DF, Evert K, De Murtas V, Gasparetti G, Mattu S, et al. V-AKT murine thymoma viral oncogene homolog\/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. Hepatology. 2012;55:1473\u201384. https:\/\/doi.org\/10.1002\/hep.25600.","journal-title":"Hepatology"},{"key":"305_CR13","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s12253-019-00708-y","volume":"26","author":"Y Lei","year":"2020","unstructured":"Lei Y, Hu Q, Gu J. Expressions of Carbohydrate Response Element Binding Protein and Glucose Transporters in Liver Cancer and Clinical Significance. Pathol Oncol Res. 2020;26:1331\u201340. https:\/\/doi.org\/10.1007\/s12253-019-00708-y.","journal-title":"Pathol Oncol Res"},{"key":"305_CR14","doi-asserted-by":"publisher","unstructured":"Dong X, Wang F, Liu C, Ling J, Jia X, Shen F, et al. Single-cell analysis reveals the intra-tumor heterogeneity and identifies MLXIPL as a biomarker in the cellular trajectory of hepatocellular carcinoma. Cell Death Discov 2021;7. https:\/\/doi.org\/10.1038\/s41420-021-00403-5.","DOI":"10.1038\/s41420-021-00403-5"},{"key":"305_CR15","doi-asserted-by":"publisher","first-page":"14740","DOI":"10.1074\/jbc.RA118.004099","volume":"293","author":"H Wang","year":"2018","unstructured":"Wang H, Dolezal JM, Kulkarni S, Lu J, Mandel J, Jackson LE, et al. Myc and ChREBP transcription factors cooperatively regulate normal and neoplastic hepatocyte proliferation in mice. J Biol Chem. 2018;293:14740\u201357. https:\/\/doi.org\/10.1074\/jbc.RA118.004099.","journal-title":"J Biol Chem"},{"key":"305_CR16","doi-asserted-by":"publisher","first-page":"21660","DOI":"10.1073\/pnas.0911316106","volume":"106","author":"X Tong","year":"2009","unstructured":"Tong X, Zhao F, Mancuso A, Gruber JJ, Thompson CB. The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation. Proc Natl Acad Sci U S A. 2009;106:21660\u20135. https:\/\/doi.org\/10.1073\/pnas.0911316106.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"305_CR17","doi-asserted-by":"publisher","unstructured":"van den Bos H, Bakker B, Taudt A, Guryev V, Colom\u00e9-Tatch\u00e9 M, Lansdorp PM, et al. Quantification of aneuploidy in mammalian systems. Methods Mol. Biol.,\u00a0Methods Mol Biol. 2019; 1896:159\u201390. https:\/\/doi.org\/10.1007\/978-1-4939-8931-7_15.","DOI":"10.1007\/978-1-4939-8931-7_15"},{"key":"305_CR18","doi-asserted-by":"publisher","unstructured":"Hoogerland JA, Lei Y, Wolters JC, de Boer JF, Bos T, Bleeker A, et al. Glucose 6 phosphate regulates hepatic bile acid synthesis in mice. Hepatology 2019;0:1\u201314. https:\/\/doi.org\/10.1002\/hep.30778.","DOI":"10.1002\/hep.30778"},{"key":"305_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(03)87164-6","volume":"87","author":"D Gisselsson","year":"2003","unstructured":"Gisselsson D. Chromosome instability in cancer: How, when, and why? Adv Cancer Res. 2003;87:1\u201329. https:\/\/doi.org\/10.1016\/S0065-230X(03)87164-6.","journal-title":"Adv Cancer Res"},{"key":"305_CR20","doi-asserted-by":"publisher","first-page":"7345","DOI":"10.1074\/jbc.M111.334599","volume":"287","author":"JA Bonzo","year":"2012","unstructured":"Bonzo JA, Ferry CH, Matsubara T, Kim JH, Gonzalez FJ. Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4\u03b1 in adult mice. J Biol Chem. 2012;287:7345\u201356. https:\/\/doi.org\/10.1074\/jbc.M111.334599.","journal-title":"J Biol Chem"},{"key":"305_CR21","doi-asserted-by":"publisher","unstructured":"Dubois V, Staels B, Lefebvre P, Verzi MP, Eeckhoute J. Control of cell identity by the nuclear receptor HNF4 in organ pathophysiology. Cells 2020;9. https:\/\/doi.org\/10.3390\/CELLS9102185.","DOI":"10.3390\/CELLS9102185"},{"key":"305_CR22","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/carcin\/17.3.609","volume":"17","author":"A Kalkuhl","year":"1996","unstructured":"Kalkuhl A, Kaestner K, Buchmann A, Schwarz M. Expression of hepatocyte-enriched nuclear transcription factors in mouse liver tumours. Carcinogenesis. 1996;17:609\u201312. https:\/\/doi.org\/10.1093\/carcin\/17.3.609.","journal-title":"Carcinogenesis"},{"key":"305_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1002\/hep.20155","volume":"39","author":"NL Lazarevich","year":"2004","unstructured":"Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, et al. Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology. 2004;39:1038\u201347. https:\/\/doi.org\/10.1002\/hep.20155.","journal-title":"Hepatology"},{"key":"305_CR24","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.1158\/0008-5472.CAN-10-0824","volume":"70","author":"BF Ning","year":"2010","unstructured":"Ning BF, Ding J, Yin C, Zhong W, Wu K, Zeng X, et al. Hepatocyte nuclear factor 4\u03b1 suppresses the development of hepatocellular carcinoma. Cancer Res. 2010;70:7640\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0824.","journal-title":"Cancer Res"},{"key":"305_CR25","doi-asserted-by":"publisher","unstructured":"Esposti DD, Hernandez-Vargas H, Voegele C, Fernandez-Jimenez N, Forey N, Bancel B, et al. Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing. Oncotarget 2016;7:31862\u201377. https:\/\/doi.org\/10.18632\/oncotarget.7364.","DOI":"10.18632\/oncotarget.7364"},{"key":"305_CR26","doi-asserted-by":"publisher","unstructured":"Atanasovska B, Rensen SS, Marsman G, Shiri-Sverdlov R, Withoff S, Kuipers F, et al. Long non-coding rnas involved in progression of non-alcoholic fatty liver disease to steatohepatitis. Cells 2021;10. https:\/\/doi.org\/10.3390\/cells10081883.","DOI":"10.3390\/cells10081883"},{"key":"305_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/jcb.27407","volume":"120","author":"S Guo","year":"2019","unstructured":"Guo S, Lu H. Novel mechanisms of regulation of the expression and transcriptional activity of hepatocyte nuclear factor 4\u03b1. J Cell Biochem. 2019;120:519\u201332. https:\/\/doi.org\/10.1002\/jcb.27407.","journal-title":"J Cell Biochem"},{"key":"305_CR28","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1101\/gad.1978810","volume":"24","author":"J Cai","year":"2010","unstructured":"Cai J, Zhang N, Zheng Y, De Wilde RF, Maitra A, Pan D. The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 2010;24:2383\u20138. https:\/\/doi.org\/10.1101\/gad.1978810.","journal-title":"Genes Dev"},{"key":"305_CR29","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.cub.2007.10.039","volume":"17","author":"FD Camargo","year":"2007","unstructured":"Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 Increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17:2054\u201360. https:\/\/doi.org\/10.1016\/j.cub.2007.10.039.","journal-title":"Curr Biol"},{"key":"305_CR30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2007.07.019","volume":"130","author":"J Dong","year":"2007","unstructured":"Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in drosophila and mammals. Cell. 2007;130:1120\u201333. https:\/\/doi.org\/10.1016\/j.cell.2007.07.019.","journal-title":"Cell"},{"key":"305_CR31","doi-asserted-by":"publisher","first-page":"8248","DOI":"10.1073\/pnas.0912203107","volume":"107","author":"KP Lee","year":"2010","unstructured":"Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:8248\u201353. https:\/\/doi.org\/10.1073\/pnas.0912203107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"305_CR32","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1073\/pnas.0911409107","volume":"107","author":"H Song","year":"2010","unstructured":"Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A. 2010;107:1431\u20136. https:\/\/doi.org\/10.1073\/pnas.0911409107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"305_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bbrc.2020.06.105","volume":"530","author":"Z Shu","year":"2020","unstructured":"Shu Z, Yi G, Deng S, Huang K, Wang Y. Hippo pathway cooperates with ChREBP to regulate hepatic glucose utilization. Biochem Biophys Res Commun. 2020;530:115\u201321. https:\/\/doi.org\/10.1016\/j.bbrc.2020.06.105.","journal-title":"Biochem Biophys Res Commun"},{"key":"305_CR34","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.celrep.2013.10.030","volume":"5","author":"S Anakk","year":"2013","unstructured":"Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ, Moore DD. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 2013;5:1060\u20139. https:\/\/doi.org\/10.1016\/j.celrep.2013.10.030.","journal-title":"Cell Rep"},{"key":"305_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.stem.2019.04.004","volume":"25","author":"BJ Pepe-Mooney","year":"2019","unstructured":"Pepe-Mooney BJ, Dill MT, Alemany A, Ordovas-Montanes J, Matsushita Y, Rao A, et al. Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration. Cell Stem Cell. 2019;25:23-38.e8. https:\/\/doi.org\/10.1016\/j.stem.2019.04.004.","journal-title":"Cell Stem Cell"},{"key":"305_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.10.001","author":"Q Liu","year":"2021","unstructured":"Liu Q, Li J, Zhang W, Xiao C, Zhang S, Nian C, et al. Glycogen accumulation and phase separation drives liver tumor initiation. Cell. 2021. https:\/\/doi.org\/10.1016\/j.cell.2021.10.001.","journal-title":"Cell"},{"key":"305_CR37","doi-asserted-by":"publisher","unstructured":"Rajas F, Dentin R, Cannella Miliano A, Silva M, Raffin M, Levavasseur F, et al. The absence of hepatic glucose-6 phosphatase\/ChREBP couple is incompatible with survival in mice. Mol Metab 2021;43. https:\/\/doi.org\/10.1016\/j.molmet.2020.101108.","DOI":"10.1016\/j.molmet.2020.101108"},{"key":"305_CR38","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1053\/j.gastro.2017.02.018","volume":"152","author":"SME Weiler","year":"2017","unstructured":"Weiler SME, Pinna F, Wolf T, Lutz T, Geldiyev A, Sticht C, et al. Induction of chromosome instability by activation of yes-associated protein and forkhead box M1 in liver cancer. Gastroenterology. 2017;152:2037-2051.e22. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.018.","journal-title":"Gastroenterology"},{"key":"305_CR39","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/febs.13604","volume":"283","author":"DE Pefani","year":"2016","unstructured":"Pefani DE, O\u2019Neill E. Hippo pathway and protection of genome stability in response to DNA damage. FEBS J. 2016;283:1392\u2013403. https:\/\/doi.org\/10.1111\/febs.13604.","journal-title":"FEBS J"},{"key":"305_CR40","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/hep.28988","volume":"65","author":"GK Michalopoulos","year":"2017","unstructured":"Michalopoulos GK. Hepatostat: Liver regeneration and normal liver tissue maintenance. Hepatology. 2017;65:1384\u201392. https:\/\/doi.org\/10.1002\/hep.28988.","journal-title":"Hepatology"},{"key":"305_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/cas.14266","volume":"111","author":"TM Loo","year":"2020","unstructured":"Loo TM, Miyata K, Tanaka Y, Takahashi A. Cellular senescence and senescence-associated secretory phenotype via the cGAS-STING signaling pathway in cancer. Cancer Sci. 2020;111:304\u201311. https:\/\/doi.org\/10.1111\/cas.14266.","journal-title":"Cancer Sci"},{"key":"305_CR42","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li T, Chen ZJ. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018;215:1287\u201399. https:\/\/doi.org\/10.1084\/jem.20180139.","journal-title":"J Exp Med"},{"key":"305_CR43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ccell.2017.04.004","volume":"31","author":"S Zhang","year":"2017","unstructured":"Zhang S, Chen Q, Liu Q, Li Y, Sun X, Hong L, et al. Hippo signaling suppresses cell ploidy and tumorigenesis through Skp2. Cancer Cell. 2017;31:669-684.e7. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.004.","journal-title":"Cancer Cell"},{"key":"305_CR44","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.tcb.2013.06.002","volume":"23","author":"SK Pandit","year":"2013","unstructured":"Pandit SK, Westendorp B, De Bruin A. Physiological significance of polyploidization in mammalian cells. Trends Cell Biol. 2013;23:556\u201366. https:\/\/doi.org\/10.1016\/j.tcb.2013.06.002.","journal-title":"Trends Cell Biol"},{"key":"305_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153740","author":"A Sargsyan","year":"2022","unstructured":"Sargsyan A, Doridot L, Hannou SA, Tong W, Srinivasan H, Ivison R, et al. HGFAC is a ChREBP regulated hepatokine that enhances glucose and lipid homeostasis. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.153740.","journal-title":"JCI Insight"},{"key":"305_CR46","doi-asserted-by":"publisher","first-page":"7959","DOI":"10.1093\/nar\/gkac624","volume":"50","author":"F Biagioni","year":"2022","unstructured":"Biagioni F, Croci O, Sberna S, Donato E, Sab\u00f2 A, Bisso A, et al. Decoding YAP dependent transcription in the liver. Nucleic Acids Res. 2022;50:7959\u201371. https:\/\/doi.org\/10.1093\/nar\/gkac624.","journal-title":"Nucleic Acids Res"},{"key":"305_CR47","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/path.1928","volume":"208","author":"T Tanaka","year":"2006","unstructured":"Tanaka T, Jiang S, Hotta H, Takano K, Iwanari H, Sumi K, et al. Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4\u03b1 in the pathogenesis of human cancer. J Pathol. 2006;208:662\u201372. https:\/\/doi.org\/10.1002\/path.1928.","journal-title":"J Pathol"},{"key":"305_CR48","doi-asserted-by":"publisher","unstructured":"Bricambert J, Alves-Guerra MC, Esteves P, Prip-Buus C, Bertrand-Michel J, Guillou H, et al. The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. Nat Commun 2018;9. https:\/\/doi.org\/10.1038\/s41467-018-04361-y.","DOI":"10.1038\/s41467-018-04361-y"},{"key":"305_CR49","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2337\/db19-0388","volume":"69","author":"JH Shi","year":"2020","unstructured":"Shi JH, Lu JY, Chen HY, Wei CC, Xu X, Li H, et al. Liver ChREBP protects against fructose-induced glycogenic hepatotoxicity by regulating L-type pyruvate kinase. Diabetes. 2020;69:591\u2013602. https:\/\/doi.org\/10.2337\/db19-0388.","journal-title":"Diabetes"},{"key":"305_CR50","doi-asserted-by":"publisher","unstructured":"Agius L, Chachra SS, Ford BE. The Protective Role of the Carbohydrate Response Element Binding Protein in the Liver: The Metabolite Perspective. Front Endocrinol (Lausanne) 2020;11. https:\/\/doi.org\/10.3389\/fendo.2020.594041.","DOI":"10.3389\/fendo.2020.594041"}],"container-title":["Cancer &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-023-00305-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-023-00305-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-023-00305-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T10:12:41Z","timestamp":1682071961000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerandmetabolism.biomedcentral.com\/articles\/10.1186\/s40170-023-00305-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1186\/s40170-023-00305-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2514060\/v1","asserted-by":"object"}]},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"assertion":[{"value":"25 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human participants: Not applicable.Animal studies: All experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of Groningen and are in line with the Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}